Current Tools and Methods in Molecular Dynamics (MD) Simulations for Drug Design

被引:72
作者
Hernandez-Rodriguez, Maricarmen [1 ]
Rosales-Hernandez, Martha C. [1 ]
Mendieta-Wejebe, Jessica E. [1 ]
Martinez-Archundia, Marlet [2 ]
Correa Basurto, Jose [2 ]
机构
[1] Inst Politecn Nacl, Lab Biofis & Biocatalisis, Escuela Super Med, Ciudad De Mexico, Mexico
[2] Inst Politecn Nacl, Lab Modelado Mol & Diseno Farmacos, Escuela Super Med, Ciudad De Mexico, Mexico
关键词
Drug design; Molecular Dynamics simulations; protein motions; drug discovery; docking studies; sampling several protein conformations; PROTEIN-LIGAND BINDING; FREE-ENERGY; FORCE-FIELD; CONFORMATIONAL ENSEMBLES; COMPUTATIONAL METHODS; NMR STRUCTURES; INHIBITORS; REFINEMENT; DOCKING; DISCOVERY;
D O I
10.2174/0929867323666160530144742
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Molecular Dynamics (MD) simulations is a computational method that employs Newton's laws to evaluate the motions of water, ions, small molecules, and macromolecules or more complex systems, for example, whole viruses, to reproduce the behavior of the biological environment, including water molecules and lipid membranes. Specifically, structural motions, such as those that are dependent of the temperature and solute/solvent are very important to study the recognition pattern of ligandprotein or protein-protein complexes, in that sense, MD simulations are very useful because these motions can be modeled using this methodology. Furthermore, MD simulations for drug design provide insights into the structural cavities required to design novel structures with higher affinity to the target. Also, the employment of MD simulations to drug design can help to refine the three-dimensional (3D) structure of targets in order to obtain a better sampling of the binding poses and more reliable affinity values with better structural advantages, because they incorporate some biological conditions that include structural motions compared to traditional docking procedures. This work analyzes the concepts and applicability of MD simulations for drug design because molecular structural motions are considered, and these help to identify hot spots, decipher structural details in the reported protein sites, as well as to eliminate sites that could be structural artifacts which could be originated from the structural characterization conditions from MD. Moreover, better free energy values for protein ligand recognition can also be obtained, and these can be validated under experimental procedures due to the robustness of the MD simulation methods.
引用
收藏
页码:3909 / 3924
页数:16
相关论文
共 85 条
  • [1] Molecular dynamics: Survey of methods for simulating the activity of proteins
    Adcock, Stewart A.
    McCammon, J. Andrew
    [J]. CHEMICAL REVIEWS, 2006, 106 (05) : 1589 - 1615
  • [2] Network visualization of conformational sampling during molecular dynamics simulation
    Ahlstrom, Logan S.
    Baker, Joseph Lee
    Ehrlich, Kent
    Campbell, Zachary T.
    Patel, Sunita
    Vorontsov, Ivan I.
    Tama, Florence
    Miyashita, Osamu
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2013, 46 : 140 - 149
  • [3] Molecular Simulation Uncovers the Conformational Space of the λ Cro Dimer in Solution
    Ahlstrom, Logan S.
    Miyashita, Osamu
    [J]. BIOPHYSICAL JOURNAL, 2011, 101 (10) : 2516 - 2524
  • [4] NEW METHOD FOR PREDICTING BINDING-AFFINITY IN COMPUTER-AIDED DRUG DESIGN
    AQVIST, J
    MEDINA, C
    SAMUELSSON, JE
    [J]. PROTEIN ENGINEERING, 1994, 7 (03): : 385 - 391
  • [5] EFFICIENT ESTIMATION OF FREE-ENERGY DIFFERENCES FROM MONTE-CARLO DATA
    BENNETT, CH
    [J]. JOURNAL OF COMPUTATIONAL PHYSICS, 1976, 22 (02) : 245 - 268
  • [6] CHARMM: The Biomolecular Simulation Program
    Brooks, B. R.
    Brooks, C. L., III
    Mackerell, A. D., Jr.
    Nilsson, L.
    Petrella, R. J.
    Roux, B.
    Won, Y.
    Archontis, G.
    Bartels, C.
    Boresch, S.
    Caflisch, A.
    Caves, L.
    Cui, Q.
    Dinner, A. R.
    Feig, M.
    Fischer, S.
    Gao, J.
    Hodoscek, M.
    Im, W.
    Kuczera, K.
    Lazaridis, T.
    Ma, J.
    Ovchinnikov, V.
    Paci, E.
    Pastor, R. W.
    Post, C. B.
    Pu, J. Z.
    Schaefer, M.
    Tidor, B.
    Venable, R. M.
    Woodcock, H. L.
    Wu, X.
    Yang, W.
    York, D. M.
    Karplus, M.
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2009, 30 (10) : 1545 - 1614
  • [7] The Amber biomolecular simulation programs
    Case, DA
    Cheatham, TE
    Darden, T
    Gohlke, H
    Luo, R
    Merz, KM
    Onufriev, A
    Simmerling, C
    Wang, B
    Woods, RJ
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) : 1668 - 1688
  • [8] The importance of employing computational resources for the automation of drug discovery
    Cecilia Rosales-Hernandez, Martha
    Correa-Basurto, Jose
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (03) : 213 - 219
  • [9] Molecular dynamics and Monte Carlo simulations for protein-ligand binding and inhibitor design
    Cole, Daniel J.
    Tirado-Rives, Julian
    Jorgensen, William L.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2015, 1850 (05): : 966 - 971
  • [10] A 2ND GENERATION FORCE-FIELD FOR THE SIMULATION OF PROTEINS, NUCLEIC-ACIDS, AND ORGANIC-MOLECULES
    CORNELL, WD
    CIEPLAK, P
    BAYLY, CI
    GOULD, IR
    MERZ, KM
    FERGUSON, DM
    SPELLMEYER, DC
    FOX, T
    CALDWELL, JW
    KOLLMAN, PA
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (19) : 5179 - 5197